HWPC(SH:688799)2022-04-19 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥291,971,291.35, representing a 23.12% increase compared to ¥237,148,716.11 in the same period last year[5] - The net profit attributable to shareholders was ¥34,091,332.01, a slight increase of 1.83% from ¥33,477,451.30 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥29,332,775.16, which is a 10.94% increase from ¥26,440,594.53 in the previous year[5] - Total operating revenue for Q1 2022 was CNY 291,971,291.35, an increase of 23.1% compared to CNY 237,148,716.11 in Q1 2021[22] - Net profit for Q1 2022 reached CNY 34,091,332.01, a slight increase of 1.8% from CNY 33,477,451.30 in Q1 2021[23] - The total comprehensive income for Q1 2022 was CNY 34,091,332.01, consistent with the net profit[23] Earnings and Expenses - The basic and diluted earnings per share decreased by 25.00% to ¥0.36 from ¥0.48 in the same period last year[6] - Research and development expenses totaled ¥16,507,184.66, accounting for 5.65% of operating revenue, down from 7.70% in the previous year[6] - Research and development expenses for Q1 2022 were CNY 16,507,184.66, a decrease of 9.6% from CNY 18,259,751.23 in Q1 2021[22] - Total operating costs for Q1 2022 were CNY 255,636,680.18, up 23.0% from CNY 207,763,220.89 in Q1 2021[22] Cash Flow - The net cash flow from operating activities decreased significantly by 66.64% to ¥14,455,015.98 from ¥43,335,784.52 in the same period last year[5] - In Q1 2022, the cash inflow from operating activities was $306,999,870.48, an increase of 10.5% compared to $277,143,828.34 in Q1 2021[25] - The net cash flow from operating activities decreased to $14,455,015.98 in Q1 2022, down 66.7% from $43,335,784.52 in Q1 2021[25] - The cash outflow from operating activities was $292,544,854.50 in Q1 2022, compared to $233,808,043.82 in Q1 2021, reflecting a 25% increase[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,919,243,493.75, reflecting a 6.77% increase from ¥1,797,533,980.72 at the end of the previous year[6] - The total assets of the company as of March 31, 2022, were approximately ¥1.92 billion, up from ¥1.80 billion at the end of 2021[19] - Total liabilities as of Q1 2022 amounted to CNY 334,259,844.11, compared to CNY 318,068,689.91 in the previous year[21] - The total liabilities include accounts payable of approximately ¥86.80 million, an increase from ¥80.90 million[19] - Total equity increased to CNY 1,584,983,649.64 in Q1 2022 from CNY 1,479,465,290.81 in Q1 2021[21] Investments and Collaborations - The company reported a significant increase in investment income of 746.04%, primarily due to higher returns from financial products[11] - The company is engaged in a project collaboration with Anhui Jiexin Pharmaceutical Technology Co., with a payment of ¥20 million for equity guarantee[11] - The company plans to invest ¥80 million in Shanghai Zhigen Pharmaceutical Technology Co., holding a 40% stake, with the first phase of investment completed in March 2022[16] - The company has signed a cooperation agreement with Anhui Jiexin Pharmaceutical Technology Co. for project research and development, with an initial payment of ¥20 million made[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,602[13] - The largest shareholder, Hunan Warner Pharmaceutical Investment Partnership, holds 37,312,000 shares, accounting for 39.78% of total shares[13] Cash and Cash Equivalents - The company's cash and cash equivalents as of March 31, 2022, were approximately ¥333.57 million, a decrease from ¥353.39 million at the end of 2021[18] - The cash and cash equivalents at the end of Q1 2022 were $316,331,068.39, down from $113,158,328.10 at the end of Q1 2021[26]